Condition: Systemic Lupus Erythematosus (SLE) · Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) · Sponsor: Bristol-Myers Squibb
The purpose of this study is to allow the continued administration of Deucravacitinib in participants with Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) who have completed study IM011074 or Study IM011132
This description comes directly from the study's public registry record.
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
First line of the email MUST contain NCT # and Site #.
Always discuss trial participation with your own doctor first.
| Local Institution - 0001 | Farmington, Connecticut, United States | Withdrawn |
| New York University School Of Medicine | New York, New York, United States | Recruiting |
| Oklahoma Medical Research Foundation | Oklahoma City, Oklahoma, United States | Recruiting |
| Local Institution - 0003 | Jackson, Tennessee, United States | Withdrawn |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06875960